New rules are reshaping the telehealth market for GLP-1s like Ozempic and Wegovy, potentially impacting access to these drugs ...

Trend alert! Split dosing, stretch dosing, skip dosing, microdosing Ozempic… People are finding creative ways to use ...

Migraines are a common ailment worldwide, affecting nearly 15% of the global population. At times, they can be debilitating enough to interfere with daily activities. Despite a multitude of treatment ...

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

Diabetics are more likely to develop Alzheimer’s than the general public. Could a popular diabetes and weight-loss drug also stave off dementia?

In a paper released in Addiction, scientists reported that people with a history of alcohol use disorder who were prescribed ...

Novo Nordisk AS and a group of insurers will pay $32 million to end litigation over its $1.8 billion acquisition of ...

Weight Watchers is Novo Nordisk's latest partnersip.

San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with ...

MHRA launches genetic study into GLP-1 drug risks as Spain investigates Novo Nordisk for potential advertising violations.